Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2015-04-10

Clinical Trial Update: A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and effectiveness of golimumab in patients with severe, persistent asthma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Simponi (golimumab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Asthma | Phase 2 | Status: WITHDRAWN